Here at Drug Discovery World (DDW) we've been publishing articles written by leading experts in the Drug Discovery, Pharmaceutical, and BioPharmaceutical industries for over 20 years.
DDW has grown as a quarterly business review of drug discovery and development, and now we've created this podcast to allow you to listen to our articles on the go.
In our journal and this podcast, we cover topics surrounding: drug discovery; drug development; business; chemistry; enabling technologies; informatics; personalised medicine; screening; therapeutics, and much more.
For the podcast we have selected recent, relevant and popular scientific articles, so that you can listen to all of the best content from Drug Discovery World. We hope you enjoy.
What does gene-based medicine have to offer?
This is the latest episode of the free DDW podcast, “What does gene-based medicine have to offer?”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW.
The articles are called “Lipidomics in biomedical research: chance and challenges” and “Exploring gene-based medicine’s true potential”.
In the first article, Afrisha Anderson, a Product Manager at Merck KGaA, discusses the opportunities and challenges in lipidomics. In the second article, Christopher Doyle, PhD, Director, IBC Services at WCG, explains why he thinks vaccines for infectious diseases are just the tip of the iceberg when thinking about the promise of gene-based medicines.
Is customisation healthcare’s secret weapon?
Podcast: Is customisation healthcare’s secret weapon?
This is the latest episode of the free DDW podcast, “Is customisation healthcare’s secret weapon?”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW. The articles are called “Optimising vaccine production through customisation” and “Exploring iPSCs for individual and population health applications”.
In the first article, “Optimising vaccine production through customisation”, John Yoshi Shyu, Ph.D. Corning Life Sciences offers an expert view on the topic. In the second article, Brad Hamilton, Founder and Chief Science Officer at GoodCell, examines the potential of induced Pluripotent Stem Cells.
You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
Scientific data management: What does your lab need?
This episode covers three narrated articles written for Volume 22, Issue 3 – Summer 2021 and Volume 22, Issue 4 – Fall 2021 of DDW.
The articles are called “The benefits of bioinformatics in genomics sequencing” and “LIMs vs ELNs – what does your lab need?”, for which Part I and Part II were published separately across DDW issues.
Dr Bongcho Kim is the new CEO of Macrogen Europe, a Netherlands-based provider of genomic sequencing services. Dr Kim’s appointment comes at a time of sustained growth for the company, which is benefitting from the rapidly expanding sequencing market. In the first article, he talks to Lu Rahman and explains the important role of bioinformatics in genomics.
The second and third article are in two parts. Researchers often ask whether a LIMS or an ELN is right for them. In this two-part series, Barry Bunin, PhD, CEO at Collaborative Drug Discovery, offers a guide to understanding what a LIMS is, and how it differs from other scientific data management systems.
A comprehensive analysis of European biotech
The latest episode of the free DDW podcast is titled “A comprehensive analysis of European biotech”. It covers three narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW, read by Megan Thomas.
The articles are “Innovation and opportunity within Europe’s biotech sector”, “Europe’s emerging biotechs: Challenges, opportunities and funding”, and “Why Switzerland continues to punch above its weight as global biotech hub”.
In the first article, Lu Rahman introduces a slice of European biotech expertise. In the second, John Macdonald of ICON examines the European biotech sector’s expertise, opportunities and potential for growth. In the third, Lu Rahman spoke to Michael Altorfer of the Swiss Biotech Association, Jan Lucht of scienceindustries, Claude Joris of BioAlps, and Carole Delauney of swiss
What do we know about lab automation?
The latest episode of the free DDW podcast is titled“What do we know about lab automation?”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW, read by Megan Thomas. The articles are “What has 2020 taught us about lab automation?” and “Enhancing drug discovery with laboratory informatics and automation”.
In 2021, the first article looked back on 2020 and Dr Patrick Courtney from SiLA consortium, Burkhard Schaefer from SiLA consortium and ASTM AnIML, and Oliver Peter from Idorsia Pharmaceuticals outlined the importance of automation in the face of global disease.
In the second article, Laura Marozsan, Scientific Marketing Specialist at Thermo Fisher Scientific, outlines the benefits of automation in drug discovery.
How to accelerate mouse model generation without reducing quality
The latest DDW Sitting Down With sponsored podcast features Dominque Bröhl and Evert-Jan Uringa, Scientific Program Managers at Taconic Biosciences who discuss how mouse model generation can be accelerated without any loss of quality.
The generation of genetically engineered custom mouse models can be a lengthy process that conflicts with the general time constraints of the drug discovery and development industry. Finding ways to shorten the time to create new mouse models is tempting but carries the risk of trading short timelines for poor quality.
Taconic Biosciences developed the ExpressMODEL® portfolio of products to achieve the industry’s fastest timelines to study cohort without compromising quality, whether embryonic stem cell (ESC), CRISPR, or random integration transgenic (RITg) methodology is used to generate a mouse model.
Listen in to learn how ExpressMODEL® accelerates timelines and which benefits it brings to your drug discovery and development program.